Case Study
Brand Strategy & Halo Effect — CGT Repositioning
Leveraging Decades of Brand Equity to Accelerate Credibility in a New Market
The Challenge
A leading life sciences company with strong brand recognition in traditional biospecimen and analytics markets sought to establish credible positioning in the emerging Cell & Gene Therapy (CGT) space.
The strategic challenge: how to leverage existing brand equity to enter a new market with different customer needs, competitive dynamics, and value propositions—without diluting their established reputation or appearing opportunistic.
They needed sophisticated brand strategy that would position them as credible CGT partner from day one, not just another supplier trying to capitalize on a hot market.
- Industry: Cell & Gene Therapy / Life Sciences
- Services: Brand Strategy, Brand Equity Assessment, Competitive Positioning, Brand Architecture, Strategic Repositioning
- Timeline: 3-month brand strategy development
- Company Type: Established biospecimen provider entering CGT market
Our Approach
01 | Brand Equity Transferability Assessment
Rather than assuming existing positioning would either transfer wholesale or need to be discarded, we assessed each brand attribute independently against what CGT buyers actually value. Attributes rooted in genuine capability — quality reputation, regulatory compliance history, technical support depth — carried real weight in the new market, since CGT customers evaluate exactly those things. Attributes rooted in how the company had gone to market — a transactional, catalog-driven sales posture and research-market language — didn’t transfer at all, and actively worked against credibility with an audience that expects a strategic partner, not a vendor.
02 | The Halo Effect – Strategic Architecture
The insight that shaped the architecture recommendation: the company had something greenfield CGT entrants could never manufacture quickly — decades of trust with the exact organizations now building CGT programs. We call this the Halo Effect: an existing reputation strong enough to lend credibility to a new offering, if the brand architecture is built to carry it rather than bury it.
The recommendation was a Master Brand structure with a CGT-specific messaging layer — retaining the existing company name and brand equity to capture the halo effect, while developing new messaging that reframed the value proposition for CGT buyers specifically. This avoided the two failure modes on either side: the credibility void of launching as an unknown separate brand, and the dilution of applying legacy messaging unchanged to a market it was never built for.
03 | Repositioning from Supplier to Solutions Partner
The repositioning wasn’t semantic, it was structural. “Biospecimen provider” described what the company sold. “CGT solutions partner” described what the company enabled — and the shift ran through every layer of the value proposition: from a transactional, catalog-based offer to an outcome-focused one built around de-risking CGT development; from order-taking to consultative partnership across the full development lifecycle; from competing on individual product specs to competing on integrated value — donor base, analytics, GMP, and documentation working together.
The Impact
Strategic Brand Direction Established
MKA provided comprehensive brand strategy that gave the client clear roadmap for CGT market entry grounded in brand equity assessment, competitive analysis, and authentic differentiation.
The “halo effect” framework enabled them to leverage decades of brand equity for immediate CGT credibility while evolving positioning to match new market requirements—capturing benefits of established brand without starting credibility-building from zero.
Defensible Competitive Positioning
The strategic focus on recallable donor base as unique differentiator created defensible competitive position. Instead of competing on generic partnership claims or undifferentiated technical capabilities, they could compete on authentic strength that directly addressed CGT developer needs and couldn’t be easily replicated.
This premium positioning justified favorable market position and enabled value-based pricing rather than commodity competition.
Brand Architecture Strategy
The brand architecture approach captured immediate credibility from existing brand equity while enabling targeted CGT positioning through differentiated messaging. This avoided costly separate brand development while preventing dilution of existing market position.
Traditional market messaging maintained product focus and transactional efficiency. CGT messaging emphasized solutions and integration. Both approaches worked under unified brand umbrella.
Solutions Provider Positioning
The evolution from “biospecimen provider” to “CGT solutions provider” represented fundamental shift in value proposition—from product-focused transactions to integrated solutions and strategic partnerships.
This repositioning supported consultative sales approach, value-based pricing, and long-term customer relationships rather than transactional, price-driven supplier dynamics.
Organizational Alignment Framework
The proof point organization (Safety, Specificity, Analysis) provided common language aligning R&D, operations, quality, marketing, and sales around coherent value story.
Product development prioritized features supporting proof points. Marketing developed content demonstrating these capabilities. Sales structured conversations around customer priorities. The framework aligned execution across all functions.
Go-to-Market Foundation
The brand strategy became foundation for all subsequent go-to-market activities. Messaging framework guided content development. Competitive positioning informed sales strategy. Value proposition shaped offering portfolio. Brand architecture determined organizational structure.
Rather than tactical marketing without strategic foundation, every execution decision flowed from disciplined brand strategy.
Facing a similar challenge?
Let’s discuss how we can help.